Oculis is a global biopharmaceutical company driven by the mission to save sight and improve eye care. As a clinical stage company, they specialize in developing innovative topical treatments in the form of eye drops for various ophthalmic diseases affecting both the front and back of the eye. Their portfolio includes groundbreaking products like OCS-01, a retinal candidate for diabetic macular edema (DME), OCS-02, a biologic candidate for dry eye disease (DED), and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma and diabetic retinopathy.

Headquartered in Switzerland, Oculis is committed to delivering life-changing treatments to patients worldwide. They have a highly differentiated pipeline, supported by a successful management team and international healthcare investors. Oculis' history dates back to Iceland, where leading ophthalmologist Prof.

Einar Stefánsson and pharmacist Prof. Thorsteinn Loftsson initiated research collaboration. Since then, Oculis has achieved significant milestones, including meeting key efficacy endpoints in clinical studies and initiating phase 3 trials to confirm their findings.

With their unwavering focus on patient-centricity, integrity, and accountability, Oculis is dedicated to making a meaningful impact in the field of ophthalmology